Jayna Patel
Nurse Practitioner · Houston, TXNPI 1043726862
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 43.7% of the total. Reporting peaked in 2024 at $94 and has fallen 54.9% since, to $43 in 2025.
Across 6 payments — averaging $36.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$94
- Acadia Pharmaceuticals Inc$43
- Boston Scientific$28
- Amgen$21
- AbbVie$15
- Chiesi USA, Inc.$15
What the payments were for
- Food & beverage$216100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 1 | $94 |
| Acadia Pharmaceuticals Inc | 1 | $43 |
| Boston Scientific | 1 | $28 |
| Amgen | 1 | $21 |
| AbbVie | 1 | $15 |
| Chiesi USA, Inc. | 1 | $15 |
How this compares
$216 in reported general payments places this provider in the 55th percentile of 5,422 nurse practitioner providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 35 | $11,011 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 38 | $5,831 |
| Tramadol Hcl | 49 | $913 |
| Potassium Chloride | 41 | $867 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 31 | $846 |
| Clonazepam | 20 | $592 |
| Lorazepam | 14 | $184 |
| Atorvastatin Calcium | 14 | $169 |
| Furosemide | 19 | $132 |
| Alprazolam | 12 | $83 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Houston
- Melanie MorrisHouston$254K
- Julie WeatherlyHouston$87K
- Katrina KingHouston$44K
- Allison TurnerHouston$37K
- Tiffany RichardsHouston$37K
- Bianca CaloHouston$36K
- Arby CohenHouston$23K
- Virginia MarxHouston$19K
- Hermeyone BellHouston$17K
- Cecilia DavisAustin$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.